NL-OMON55845招募中2 期
Study of pembrolizumab combined with ataluren in Patients with metastatic pMMR and dMMR colorectal cancer adenocarcinomas or metastatic dMMR endometrial carcinoma: the ATAPEMBRO study. - ATAPEMBRO
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 47
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Metastatic or irresectable locally advanced mismatch repair proficient or
- •deficient colorectal carcinoma or mismatch repair deficient endometrial
- •carcinoma or mismatch repair deficient stomach carcinoma or mismatch repair
- •deficient small bowel carcinoma carcinoma
- •- Have received or refused at least one chemotherapy treatment for metastatic
- •- Life expectancy greater than 3 months
- •- Normal organ and marrow function (as defined in protocol)
- •- Be willing and able to provide metastasis tissue pre and post treatment by
- •core or excissional biopsy.
排除标准
- •- (Partner is) currently pregnant or breastfeeding or is planning to become
- •pregnant or nurture a child during the duration of the trial and a designated
- •period thereafter.
- •- Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti
- •OX-40, anti-CD40 or anti-CTLA-4.
- •- Active central nervous system metastsasis or carcinomateus meningitis
- •- (History of) auto-immune disease
- •- Immunodeficiency or use of immunosuppressing drugs.
- •- Active infection
- •- Uncontrolled intercurrent disease (for example hearth failure)
- •- (History of) active Tuberculosis
- •- HIV, Hep A, Hep B.
研究者
相似试验
进行中（未招募）
1 期
Combining Ataluren with immunotherapy for the treatment of colorectal and endometrial cancer: the ATAPEMBRO study.Mismatch repair deficient and proficient metestatic colorectal carcinoma and mismatch repair deficient metastatic endometrial carcinomaEUCTR2017-004752-34-NLAmsterdam University Medical Centers location AMC47
进行中（未招募）
1 期
Study of Pembrolizumab combined with Ataluren in Patients with metastatic pMMR and dMMR colorectal cancer adenocarcinomas or metastatic dMMR endometrial carcinoma: the ATAPEMBRO studyCTIS2023-509457-31-00Amsterdam UMC47
尚未招募
不适用
Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMRColorectal Cacrinoma or Metastatic dMMR Endometrial Carcinoma: theATAPEMBRO Study.NL-OMON23548Amsterdam UMC location AMC47
招募中
1 期
Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO StudyEndometrium CancerColorectal CancerNCT04014530Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)47
进行中（未招募）
2 期
A phase 2 study of pembrolizumab in combination with olaparib in patients with cervical cancer previously treated with platinum-based chemotherapyrecurrent or metastatic cervical cancercervical cancer ,Pembrolizumab,OlaparibJPRN-jRCT2031210096Hasegawa Kosei28